何燕燕, 王利华. 硫酸吲哚酚在慢性肾脏病并发心血管疾病进展中的作用[J]. 临床肾脏病杂志, 2024, 24(2): 136-142. DOI: 10.3969/j.issn.1671-2390.2024.02.008
    引用本文: 何燕燕, 王利华. 硫酸吲哚酚在慢性肾脏病并发心血管疾病进展中的作用[J]. 临床肾脏病杂志, 2024, 24(2): 136-142. DOI: 10.3969/j.issn.1671-2390.2024.02.008
    He Yan-yan, Wang Li-hua. Role of indoxyl sulfate in the progression of chronic kidney disease and associated cardiovascular diseases[J]. Journal of Clinical Nephrology, 2024, 24(2): 136-142. DOI: 10.3969/j.issn.1671-2390.2024.02.008
    Citation: He Yan-yan, Wang Li-hua. Role of indoxyl sulfate in the progression of chronic kidney disease and associated cardiovascular diseases[J]. Journal of Clinical Nephrology, 2024, 24(2): 136-142. DOI: 10.3969/j.issn.1671-2390.2024.02.008

    硫酸吲哚酚在慢性肾脏病并发心血管疾病进展中的作用

    Role of indoxyl sulfate in the progression of chronic kidney disease and associated cardiovascular diseases

    • 摘要: 近年来,慢性肾脏病(chronic kidney disease,CKD)的患病率和病死率逐年上升,心血管疾病(cardiovascular disease,CVD)是CKD高发病率和高病死率的原因之一。这种高风险不能完全用传统的心血管危险因素来解释,CKD特有的危险因素尿毒症毒素已经成为解释CKD相关CVD的关键因素。本综述通过对典型的蛋白质结合类毒素硫酸吲哚酚(indoxyl sulfate,IS)进行总结,阐述目前它在CKD发生发展中的作用机制,并且通过其在动脉粥样硬化、血管钙化、充血性心力衰竭、心律失常四个方面的作用机制进行展开,显示IS与CKD相关CVD之间存在的关联。强调了有效减少血清中IS的治疗措施包括限制蛋白质的摄入、调节肠道菌群、口服肠道吸附剂以及增强IS清除率的创新透析方法。其中白蛋白结合竞争剂似乎是去除蛋白质结合类毒素的有效方法,未来需要发现更多清除IS的方法,并进一步确定其是否能延缓CKD的进展和减少CKD相关CVD的发生。

       

      Abstract: In recent years, both morbidity and mortality of chronic kidney disease (CKD) have been rising rapidly and cardiovascular disease (CVD) is one of major causes. Traditional cardiovascular risk factors cannot fully explain this phenomenon. Therefore such CKD-specific risk factors as uremic toxins (UTs) have emerged as crucial players. This review focused upon typical protein-binding toxin of indoxyl sulfate (IS). It described the mechanisms of effects in the occurrence and development of CKD and depicted an association with IS and CKD-related CVD by four aspects of atherosclerosis, arteriosclerosis, congestive heart failure and arrhythmias. Also effective therapeutic measures of reducing serum level of IS were introduced, including restriction of protein intake, modulation of intestinal flora, using oral intestinal adsorbents and innovative dialysis approaches of enhancing IS clearance. And albumin-binding competitors appear to be an effective removal of protein-binding UTs. In the future, more modes of IS clearance shall be discovered and verified whether or not they can slow the progression of CKD and lower the incidence of CKD-related cardiovascular disease in CKD.

       

    /

    返回文章
    返回